Xiaohui Zhou, Huimei Huang, Wanmeng Cui, Yifang Wang, Wenqi Luo, Liudmila Matskova, Xiaoying Zhou
Life Science Institute, Guangxi Medical University, Nanning, Guangxi, China (mainland)
Med Sci Monit 2020; 26:e922836
Available online: 2020-04-09
Aberrant expression of cadherin family members and their possible biological function have been widely studied in renal cell carcinoma (RCC). However, the expression of cadherin 4 (CDH4) and its value in RCC diagnosis and prognosis remains elusive.
MATERIAL AND METHODS: The TCGA database was used to analyze the expression of CDH4 and its clinical parameters and prognosis in 891 RCC patients. In addition, real-time PCR was used to verify the transcription of CDH4 in renal clear cell carcinoma tissue, and the distribution of protein was observed by immunohistochemical staining.
RESULTS: We found that the mRNA level of CDH4 was elevated in primary RCC in contrast with normal kidney samples using bioinformatics analysis based on the TCGA database. Among the 3 main subtypes of RCC, transcriptional CDH4 was significantly increased in KIRC and KIRP, while it was downregulated in KICH. Interestingly, CDH4 mRNA gradually decreased with the progression of KIRC and KIRP. The transcription of CDH4 in the primary tumor of KIRP patients at T3-T4 stages and KIRC patients with lymph node and distant metastasis were decreased significantly. Overall survival (OS) showed that KIRC and KICH patients with lower expression of CDH4 had worse outcomes.
CONCLUSIONS: The transcriptional level of CDH4 may serve as an effective diagnostic and prognostic biomarker for RCC patients.
Keywords: Biological Markers, Cadherins, Carcinoma, Renal Cell, Prognosis